Table 2.
Final Results – Details
| Disaggregated Costs (Discounted) | Costs | Incremental Costs | |||
|---|---|---|---|---|---|
| Pegcetacoplan | Eculizumab | Ravulizumab | Pegcetacoplan vs Eculizumab | Pegcetacoplan vs Ravulizumab | |
| Drug costs | 1,456,569 € | 1,518,947 € | 1,509,183 € | −62,378 € | −52,614 € |
| Complement inhibitor (total) | 1,455,724 € | 1,518,223 € | 1,508,460 € | −62,500 € | −52,736 € |
| Supportive treatments | 846 € | 723 € | 723 € | 122 € | 122 € |
| Administration costs | 578 € | 1874 € | 981 € | −1296 € | −403 € |
| Vaccination costs | 0 € | 0 € | 0 € | 0 € | 0 € |
| Health state costs | 22,570 € | 59,608 € | 59,328 € | −37,038 € | −36,758 € |
| Costs of managing complications | 10,452 € | 33,343 € | 33,063 € | −22,891 € | −22,611 € |
| Costs of blood transfusion | 5973 € | 20,120 € | 20,120 € | −14,147 € | −14,147 € |
| Other resource use costs | 6145 € | 6145 € | 6145 € | 0 € | 0 € |
| AE costs | 3737 € | 5334 € | 5334 € | −1597 € | −1597 € |
| Total costs | 1,483,454 € | 1,585,763 € | 1,574,826 € | −102,309 € | −91,372 € |
Note: Bold text refers to main titles and important results.